BSE filing, NSE: PRIVISCL. Summary written from the filing by ALFA Finder's alert engine.
Privi Speciality Chemicals Ltd: key numbers
- Share price
- ₹3,500.00
- Market cap
- ₹13,672 Cr
- Revenue (annual)
- ₹2,564 Cr
- Net profit (annual)
- ₹327.5 Cr
- P/E (TTM)
- 39.1×Sector 34.1×
- Promoter holding
- 60.60%+0.00% QoQ
- FII holding
- 2.78%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Privi Speciality Chemicals Ltd
All →Privi Speciality Chemicals Dividend
Privi Speciality Chemicals declared an interim dividend of Rs 5 per equity share for FY 2026-27 at its 29 October 2026 board meeting. Record date is 04 November 2026 and payment by 25 November 2026.
Privi Speciality Chemicals Q2 FY27 Results: Net Profit ₹117.5 Cr, Up 30.3% YoY
Privi Speciality Chemicals Ltd reported revenue from operations of ₹760.5 Cr (+12.1% YoY) and net profit of ₹117.5 Cr (+30.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹117.5 Cr · +30.3% YoY
Privi Speciality Chemicals Acquisition
Privi Speciality Chemicals' NCLT-convened equity shareholder meeting approved the Scheme of Amalgamation of Privi Fine Sciences and Privi Biotechnologies into the company. The special resolution passed with requisite majority, subject to scrutinizer report.
Privi Speciality Chemicals Board Meeting Date
Privi Speciality Chemicals intimated its board meeting is scheduled for October 29, 2026, to consider Q1/H1 results and an interim dividend. Items are proposed only and not yet decided.
Privi Speciality Chemicals Other Announcement
Privi Speciality Chemicals Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI regulatory requirements.
Privi Speciality Chemicals Capital Structure Change
SBI Mutual Fund sold 18,400 shares of Privi Speciality Chemicals Ltd via open market, reducing its stake from 7.3905% to 7.3434%.
Other acquisition announcements
All →Laurus Labs Acquisition Worth ₹32.5 Cr
Laurus Labs approved acquiring 52% of SI & C Resins for Rs. 32.50 Crore. The acquisition makes SI&C a subsidiary for peptide resin manufacturing.
- Value
- ₹32.50 Cr
Laurus Labs Acquisition Worth ₹35.63 Cr
Laurus Labs approved buying 60% of Canada-based CRO Galenvs Sciences for USD 3.75 million (₹35.63 Cr). The deal adds an oligonucleotide R&D arm and North American presence.
- Value
- ₹35.63 Cr
Raghav Productivity Enhancers Acquisition
RPEL acquires 80% of RPEL TRLK Silicatech Private Limited for a nominal cash subscription. The target manufactures silica ramming mass and other refractories in India.
Container Corporation of India Acquisition Worth ₹485.9 Cr
CONCOR placed an order with Braithwaite & Co for 24 rakes of BLSS wagons. The deal, including GST, values at Rs.485.93 Crores.
- Value
- ₹485.9 Cr
- Execution
- Delivery by 20.06.2028
- BLSS wagons (fleet)
- 24.0 rakes
Embassy Developments Acquisition Worth ₹32.65 Cr
Embassy Developments signed an SPA to acquire 50% of Embassy Columbia Pacific ASL for ₹32.65 Crore. The JV will become wholly owned upon closing by December 2026.
- Value
- ₹32.65 Cr
- Execution
- Within the current quarter ending on December 31, 2026
MosChip Technologies Acquisition Worth ₹266.7 Cr
MosChip will acquire Vayavya Labs for Rs.266.71 Crore in cash and shares. Completion awaits RBI and exchange approvals and shareholder approval of a preferential issue.
- Value
- ₹266.7 Cr
- Execution
- Within 15 days of the later of receipt of all requisite approvals or shareholder approval of the preferential issue to VLPL sellers